News
AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
2 Apr 24
Earnings, Earnings Beats, Earnings Misses, News
Earnings Scheduled For April 2, 2024
2 Apr 24
Earnings
Preview: AIM ImmunoTech's Earnings
1 Apr 24
Earnings
Earnings Scheduled For March 26, 2024
26 Mar 24
Earnings
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
25 Mar 24
Long Ideas, News, Penny Stocks, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
AIM ImmunoTech Launches CEO Corner Platform
7 Mar 24
News
AIM ImmunoTech Announces First Subject Dosed In Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca's Imfinzi For Pancreatic Cancer
14 Feb 24
Biotech, News, General
12 Health Care Stocks Moving In Monday's After-Market Session
12 Feb 24
Movers
AIM ImmunoTech Reports Topline Results From Phase 2 Study Evaluating Ampligen For Treatment Of Post-COVID Conditions
8 Feb 24
Biotech, News, General
Press releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
18 Apr 24
News, Management, Press Releases
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
15 Apr 24
News, Management, Press Releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
11 Apr 24
News, Management, Press Releases
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
10 Apr 24
Health Care, Press Releases, General
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2 Apr 24
Earnings, News, Press Releases
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
28 Mar 24
News, Press Releases
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
26 Mar 24
Press Releases
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
25 Mar 24
Health Care, Analyst Ratings, Press Releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
22 Mar 24
Economics, Press Releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
20 Mar 24
Press Releases
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
15 Mar 24
News, Press Releases
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
29 Feb 24
Press Releases
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
14 Feb 24
Press Releases, General
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
8 Feb 24
Press Releases